SAN DIEGO, April 17, 2014 /PRNewswire/ -- Shareholder
rights law firm Robbins Arroyo LLP is investigating whether certain
officers and directors of Halozyme Therapeutics, Inc. (NASDAQ:
HALO) breached their fiduciary duties to shareholders.
Halozyme is a biopharmaceutical company that researches, develops,
and commercializes human enzymes that facilitate the delivery of
injected drugs and fluids.
View the investigation on the law firm's Shareholder Rights
Blog:
www.robbinsarroyo.com/shareholders-rights-blog/halozyme-therapeutics-inc/
Halozyme Shares Drop on Halt of PEGPH20 Phase 2
Trial
On April 4, 2014, Halozyme issued
a press release announcing that patient enrollment and dosing of
PEGPH20 would be halted in the Phase 2 trial of evaluating PEGPH20
in patients with pancreatic cancer. The suspension of the
trial followed the recommendation of the independent Data
Monitoring Committee, while it assess "clinical data that indicates
a possible difference in the thromboembolic event rate between the
group of patients treated with PEGPH20, nab-paclitaxel and
gemcitabine versus the group of patients treated with
nab-paclitaxel and gemcitabine without PEGPH20." On this news,
shares of Halozyme fell $3.16, or
27%, to close at $8.43 on
April 4, 2014. Then on
April 9, 2014, Halozyme announced
that the U.S. Food and Drug Administration had placed a clinical
hold on patient enrollment and dosing of PEGPH20.
Halozyme Residential Shareholders Have Legal
Options
Robbins Arroyo LLP highlights that Halozyme shareholders have
the option to pursue a shareholder litigation demand or shareholder
derivative action through which shareholders aim to hold insider
wrongdoers accountable for their actions, prevent future
misconduct, and bring long-term value back to the company.
Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003,
DDonahue@robbinsarroyo.com, or via the shareholder information form
on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in
shareholder rights law. The firm represents individual and
institutional investors in shareholder derivative and securities
class action lawsuits, and has helped its clients realize more than
$1 billion of value for themselves
and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a
similar outcome.
Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com
Logo -
http://photos.prnewswire.com/prnh/20130103/MM36754LOGO
SOURCE Robbins Arroyo LLP